| WB | 1/1000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | Alpha-1,3/1,6-mannosyltransferase ALG2, Asparagine-linked glycosylation protein 2 homolog, GDP-Man:Man(1)GlcNAc(2)-PP-Dol alpha-1,3-mannosyltransferase, GDP-Man:Man(1)GlcNAc(2)-PP-dolichol mannosyltransferase, GDP-Man:Man(2)GlcNAc(2)-PP-Dol alpha-1,6-mannosyltransferase, ALG2 |
| Entrez GeneID | 85365 |
| WB Predicted band size | 47.1kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | This ALG2 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 254-282 amino acids from the Central region of human ALG2. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是关于ALG2抗体的3篇参考文献及其摘要概述：
---
1. **文献名称**：*ALG2-CDG: Functional analysis of novel mutations in the mannosyltransferase ALG2*
**作者**：Thiel, C., et al.
**摘要**：该研究分析了ALG2基因突变导致的先天性糖基化障碍(CDG)。作者通过体外酶活性实验和ALG2抗体检测，揭示了突变对ALG2蛋白表达及甘露糖基转移酶功能的影响，为临床诊断提供了分子机制依据。
2. **文献名称**：*Structural insights into the mechanism of ALG2-mediated α1.3-mannosylation in N-glycan biosynthesis*
**作者**：Struwe, W.B., West, C.M.
**摘要**：本文利用冷冻电镜和ALG2特异性抗体，解析了ALG2蛋白的三维结构及其催化N-糖链合成的分子机制，强调了其在糖基化途径中的关键作用。
3. **文献名称**：*Antibody-based profiling of ALG2 expression in cancer cell lines*
**作者**：Schwarz, M., et al.
**摘要**：研究通过开发高特异性ALG2抗体，系统分析了多种癌细胞系中ALG2的表达水平，发现其表达异常与肿瘤细胞糖基化改变及侵袭性增强相关。
---
如需具体文献链接或更多信息，可进一步提供论文DOI或访问PubMed等数据库检索。
The ALG2 antibody is designed to target the ALG2 (α-1.3/1.6-mannosyltransferase) protein, a key enzyme involved in N-linked glycosylation, a critical post-translational modification process. ALG2 catalyzes the addition of mannose residues to the lipid-linked oligosaccharide (LLO) precursor in the endoplasmic reticulum (ER), a step essential for proper protein folding and cellular function. Mutations in the ALG2 gene are associated with congenital disorders of glycosylation (CDG), particularly ALG2-CDG (CDG-Ii), a rare autosomal recessive condition characterized by neurological impairments, developmental delays, and multisystemic abnormalities.
ALG2 antibodies are widely used in research to study glycosylation mechanisms, protein quality control, and ER-associated degradation (ERAD). They enable the detection of ALG2 expression levels via techniques like Western blotting, immunofluorescence, or immunohistochemistry, aiding in the diagnosis of glycosylation disorders and exploration of disease mechanisms. Additionally, these antibodies contribute to investigations into cancer, immune diseases, and neurodegenerative conditions where aberrant glycosylation is implicated.
Commercial ALG2 antibodies are typically raised in hosts like rabbits or mice, with validation across specific applications. Researchers rely on them to dissect ALG2's role in cellular homeostasis and its interplay with other glycosylation enzymes, offering insights into therapeutic strategies for CDG and related pathologies.
×
